Does the media favor CMPS or PTCT?

In the previous week, Compass Pathways had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 8 mentions for Compass Pathways and 7 mentions for PTC Therapeutics. Compass Pathways' average media sentiment score of 1.06 beat PTC Therapeutics' score of 0.34 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LNTH or CMPS more profitable?

Lantheus has a net margin of 18.05% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Compass Pathways N/A -31.07% -11.40%

Does the media prefer LNTH or CMPS?

In the previous week, Compass Pathways had 2 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Compass Pathways and 6 mentions for Lantheus. Compass Pathways' average media sentiment score of 1.06 beat Lantheus' score of 0.71 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CMPS or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$3.15 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is CMPS or SRRK more profitable?

Compass Pathways' return on equity of -31.07% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to CMPS or SRRK?

In the previous week, Compass Pathways had 3 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Compass Pathways and 5 mentions for Scholar Rock. Compass Pathways' average media sentiment score of 1.06 beat Scholar Rock's score of 0.46 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CMPS or XENE more profitable?

Compass Pathways' return on equity of -31.07% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media refer more to CMPS or XENE?

In the previous week, Compass Pathways had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 8 mentions for Compass Pathways and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Compass Pathways' score of 1.06 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, COGT or CMPS?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Compass Pathways N/A N/A -$287.86M -$3.15 N/A

Is COGT or CMPS more profitable?

Compass Pathways' return on equity of -31.07% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Compass Pathways N/A -31.07% -11.40%

Does the media favor COGT or CMPS?

In the previous week, Compass Pathways had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Compass Pathways and 2 mentions for Cogent Biosciences. Compass Pathways' average media sentiment score of 1.06 beat Cogent Biosciences' score of 0.45 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compass Pathways (CMPS) Competitors

$11.69 +0.02 (+0.19%)

As of 09:54 AM Eastern

Compare

CMPS vs. PTCT, LNTH, SRRK, XENE, and COGT

Should you buy Compass Pathways stock or one of its competitors? MarketBeat compares Compass Pathways with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Pathways include PTC Therapeutics (PTCT), Lantheus (LNTH), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Compass Pathways compare to PTC Therapeutics?

Compass Pathways (NASDAQ:CMPS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Compass Pathways has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Compass Pathways' return on equity of -31.07% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Compass Pathways has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Compass Pathways had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 8 mentions for Compass Pathways and 7 mentions for PTC Therapeutics. Compass Pathways' average media sentiment score of 1.06 beat PTC Therapeutics' score of 0.34 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways presently has a consensus target price of $24.15, indicating a potential upside of 106.97%. PTC Therapeutics has a consensus target price of $92.29, indicating a potential upside of 18.30%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts clearly believe Compass Pathways is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has higher revenue and earnings than Compass Pathways. PTC Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

Summary

Compass Pathways beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Compass Pathways (NASDAQ:CMPS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Lantheus has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.40	$233.56M	$4.15	25.16
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lantheus currently has a consensus target price of $110.43, suggesting a potential upside of 5.77%. Compass Pathways has a consensus target price of $24.15, suggesting a potential upside of 106.97%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

In the previous week, Compass Pathways had 2 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Compass Pathways and 6 mentions for Lantheus. Compass Pathways' average media sentiment score of 1.06 beat Lantheus' score of 0.71 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Compass Pathways	N/A	-31.07%	-11.40%

Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market.

Summary

Lantheus and Compass Pathways tied by winning 8 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Scholar Rock?

Compass Pathways (NASDAQ:CMPS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Compass Pathways has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Compass Pathways had 3 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Compass Pathways and 5 mentions for Scholar Rock. Compass Pathways' average media sentiment score of 1.06 beat Scholar Rock's score of 0.46 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways currently has a consensus price target of $24.15, indicating a potential upside of 106.97%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 10.54%. Given Compass Pathways' higher possible upside, equities analysts plainly believe Compass Pathways is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Compass Pathways' return on equity of -31.07% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Scholar Rock	N/A	-163.52%	-96.67%

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Compass Pathways beats Scholar Rock on 10 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Xenon Pharmaceuticals?

Compass Pathways (NASDAQ:CMPS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Compass Pathways has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Compass Pathways has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A

Compass Pathways' return on equity of -31.07% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Compass Pathways presently has a consensus price target of $24.15, indicating a potential upside of 106.97%. Xenon Pharmaceuticals has a consensus price target of $77.20, indicating a potential upside of 16.90%. Given Compass Pathways' higher possible upside, equities analysts plainly believe Compass Pathways is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Compass Pathways had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 8 mentions for Compass Pathways and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Compass Pathways' score of 1.06 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Compass Pathways (NASDAQ:CMPS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Cogent Biosciences presently has a consensus target price of $45.90, indicating a potential upside of 19.84%. Compass Pathways has a consensus target price of $24.15, indicating a potential upside of 106.97%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts clearly believe Compass Pathways is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Cogent Biosciences is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

In the previous week, Compass Pathways had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Compass Pathways and 2 mentions for Cogent Biosciences. Compass Pathways' average media sentiment score of 1.06 beat Cogent Biosciences' score of 0.45 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

46.2% of Compass Pathways shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market.

Compass Pathways' return on equity of -31.07% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Compass Pathways	N/A	-31.07%	-11.40%

Summary

Compass Pathways beats Cogent Biosciences on 11 of the 14 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67B	$9.65B	$6.89B	$12.28B
Dividend Yield	N/A	1.60%	2.67%	9.39%
P/E Ratio	-3.70	26.62	27.07	23.95
Price / Sales	N/A	18.93	519.31	90.33
Price / Cash	N/A	15.03	26.68	47.25
Price / Book	-21.22	6.14	10.62	6.14
Net Income	-$287.86M	$179.69M	$3.60B	$331.74M
7 Day Performance	-12.85%	-0.98%	-1.26%	-1.82%
1 Month Performance	-6.86%	4.88%	1.07%	-1.45%
1 Year Performance	161.66%	13.70%	23.63%	16.32%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	3.3562 of 5 stars	$11.69 +0.2%	$24.15 +106.6%	+171.4%	$1.58B	N/A	N/A	120	Gap Down
PTCT PTC Therapeutics	3.3925 of 5 stars	$81.33 -4.1%	$91.57 +12.6%	+63.8%	$7.04B	$1.73B	N/A	1,410	Analyst Forecast
LNTH Lantheus	2.8585 of 5 stars	$105.39 -0.2%	$108.29 +2.7%	+48.8%	$6.88B	$1.54B	25.40	1,193
SRRK Scholar Rock	1.9433 of 5 stars	$54.70 -3.5%	$56.00 +2.4%	+24.4%	$6.80B	N/A	N/A	140	News Coverage
XENE Xenon Pharmaceuticals	2.8944 of 5 stars	$67.72 -1.7%	$77.20 +14.0%	+109.1%	$6.66B	$7.50M	N/A	210	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. PTCT, LNTH, SRRK, XENE, and COGT

How does Compass Pathways compare to PTC Therapeutics?

Summary

How does Compass Pathways compare to Lantheus?

Summary

How does Compass Pathways compare to Scholar Rock?

Summary

How does Compass Pathways compare to Xenon Pharmaceuticals?

Summary

How does Compass Pathways compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. PTCT, LNTH, SRRK, XENE, and COGT

How does Compass Pathways compare to PTC Therapeutics?

Is CMPS or PTCT more profitable?

Which has more risk and volatility, CMPS or PTCT?

Do institutionals & insiders have more ownership in CMPS or PTCT?

Does the media favor CMPS or PTCT?

Do analysts recommend CMPS or PTCT?

Which has stronger valuation and earnings, CMPS or PTCT?

Summary

How does Compass Pathways compare to Lantheus?

Which has better earnings and valuation, LNTH or CMPS?

Do institutionals and insiders have more ownership in LNTH or CMPS?

Do analysts rate LNTH or CMPS?

Does the media prefer LNTH or CMPS?

Is LNTH or CMPS more profitable?

Which has more volatility & risk, LNTH or CMPS?

Summary

How does Compass Pathways compare to Scholar Rock?

Which has more volatility & risk, CMPS or SRRK?

Does the media refer more to CMPS or SRRK?

Do analysts recommend CMPS or SRRK?

Which has preferable earnings & valuation, CMPS or SRRK?

Is CMPS or SRRK more profitable?

Do insiders and institutionals have more ownership in CMPS or SRRK?

Summary

How does Compass Pathways compare to Xenon Pharmaceuticals?

Which has more volatility & risk, CMPS or XENE?

Which has preferable valuation and earnings, CMPS or XENE?

Is CMPS or XENE more profitable?

Do insiders & institutionals believe in CMPS or XENE?

Do analysts prefer CMPS or XENE?

Does the media refer more to CMPS or XENE?

Summary

How does Compass Pathways compare to Cogent Biosciences?

Do analysts prefer COGT or CMPS?

Which has preferable earnings & valuation, COGT or CMPS?

Does the media favor COGT or CMPS?

Do insiders and institutionals believe in COGT or CMPS?

Which has more volatility and risk, COGT or CMPS?

Is COGT or CMPS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools